Question

PDE 4 inhibitor used in COPD

• A. Montelukast
• B. Roflumilast
• C. Cromoglicate
• D. Omalizumab

Hint:

PDE4 inhibitors like roflumilast help control inflammation in COPD by modulating intracellular signaling pathways, improving symptoms and reducing exacerbations.

Answer 1

The Correct Option is B

Phosphodiesterase-4 (PDE4) inhibitors are a class of drugs that reduce inflammation by preventing the breakdown of cyclic AMP (cAMP) in inflammatory cells. - Roflumilast is a selective PDE4 inhibitor approved for use in chronic obstructive pulmonary disease (COPD). By inhibiting PDE4, it increases intracellular cAMP levels, leading to reduced release of pro-inflammatory mediators.
- This results in decreased inflammation in the lungs, improved airflow, and reduced exacerbations in COPD patients.
- Other options: - Montelukast is a leukotriene receptor antagonist used in asthma, not a PDE4 inhibitor.
- Cromoglicate (cromolyn sodium) is a mast cell stabilizer used in asthma prophylaxis.
- Omalizumab is an anti-IgE monoclonal antibody used for allergic asthma.
Hence, roflumilast is the correct PDE4 inhibitor used in COPD management.

Answer 2

The question is asking for a drug that inhibits the PDE4 enzyme and is specifically used in COPD, so checking the mechanism and approved use of each drug in turn will identify it.

1. Montelukast: Montelukast blocks leukotriene receptors, cutting down the inflammatory effects of leukotrienes in the airway. It is used for asthma and allergic conditions, and it does not touch PDE4 at all.
2. Roflumilast: Roflumilast selectively inhibits phosphodiesterase-4, the enzyme that normally breaks down cyclic AMP inside inflammatory cells. By blocking PDE4, it lets cAMP levels stay elevated, which dampens the release of inflammatory mediators in the lungs. It is specifically approved as an add-on treatment to cut down exacerbations in severe COPD with chronic bronchitis.
3. Cromoglicate: Cromoglicate stabilizes mast cell membranes so they release fewer inflammatory mediators when triggered. It is used mainly for asthma prevention and allergic conditions, not for PDE4 inhibition or COPD.
4. Omalizumab: Omalizumab is a monoclonal antibody that binds free IgE, preventing it from triggering allergic cascades. It is reserved for moderate to severe allergic asthma and has no PDE4 activity.

Only roflumilast works through PDE4 inhibition, and it is the one of these four specifically indicated for COPD.

So the correct answer is Roflumilast.